-+ 0.00%
-+ 0.00%
-+ 0.00%

Citius Pharma Subsidiary Announces Commercial Launch Of LYMPHIR, IL-2 Receptor-Directed Fusion Protein For r/r Stage I–III Cutaneous T-Cell Lymphoma Treatment

Benzinga·12/01/2025 17:06:50
Listen to the news

Citius Oncology, Inc. ("Citius Oncology") (NASDAQ:CTOR), the oncology-focused subsidiary of Citius Pharmaceuticals, Inc. ("Citius Pharma") (NASDAQ:CTXR), today announced the commercial launch of LYMPHIR™ (denileukin diftitox-cxdl). LYMPHIR is a novel IL-2 receptor-directed fusion protein approved by the U.S. Food and Drug Administration (FDA) for the treatment of adult patients with relapsed or refractory (r/r) Stage I–III cutaneous T-cell lymphoma (CTCL) after at least one prior systemic therapy.